Phase I trial of CHP-HER2-pulsed dendritic cell vaccine for advanced breast and non-small cell lung cancer
Not Applicable
Completed
- Conditions
- breast cancer, non-small cell lung cancer
- Registration Number
- JPRN-UMIN000001295
- Lead Sponsor
- Hokkaido University Hospital, Kyushu University Hospital at Beppu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
Pregnancy, contra-ceptive during trial entry. Milking. Serious bleeding tendency. Risk of thrombosis. Acitive infection, HIV, HCV and HBV-positives. Serious pleural effusion, ascites and pericardial effusion. Probable alternative drug treatment during the trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method adverse effect profiles, including events, frequency and grades.
- Secondary Outcome Measures
Name Time Method HER2-specific immune responses anti-tumor effects